Clinical trials: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma
Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma.
- Conditions
- Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
- Trial name
- NCT07583810
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma
Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.
- Trial name
- IRIS (NCT01514344)
- Testing
- intralesional rituximab, supplemental autologous serum
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Andres J. M. Ferreri
Lymphoma
R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
The purpose of this study is to determine how efficient the combination of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II non-conjunctival ocular adnexal MALT lymphoma…
- Trial name
- NCT01427114
- Testing
- rituximab, cyclophosphamide, vincristine, and prednisolone
- Where
- 2 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Konkuk University Medical Center